Recombinant VZV (strain Oka vaccine) Envelope Glycoprotein E is produced by our Mammalian expression system and the target gene encoding Ser31-Tyr538 is expressed with a 6His tag at the C-terminus.

Envelope Glycoprotein E; gE

58.4 kDa

58-100 kDa, reducing conditions

Supplied as a 0.2 μm filtered solution of PBS, pH7.4.

The product is shipped on dry ice pack.Upon receipt, store it immediately at the temperature listed below.

Shingles (Herpes zoster) is a painful, blistering rash caused by reactivation of latent varicella-zoster virus (VZV) and most frequently occurs in elderly and immunocompromised individuals. A recombinant glycoprotein E (gE) subunit vaccine was developed to overcome the unmet medical need for a better vaccine. The subunit vaccine consists of the recombinant VZV gE and the AS01B Adjuvant System. gE was selected as the vaccine antigen because it is the most abundant glycoprotein expressed by VZV-infected cells and it induces both neutralizing antibody and CD4 T-cell responses. VZV gE protein is essential for viral replication. Targeted mutations of gE that are compatible with VZV replication in cultured cells have varying phenotypes in skin and T-cell xenografts in the SCID mouse model of VZV pathogenesis in vivo.